natgillin/translations-raw huggingface dataset:
optionally one or more pharmaceutically acceptable excipients. The formulation according to claim 1, further comprising an aqueous vehicle. The formulation according to claim 2, wherein the aqueous vehicle is saline. 
Formulacija sukladno patentnom zahtjevu 1, naznačena time što formulacija takođe sadrži vodeni nosač. Formulacija sukladno patentnom zahtjevu 2, naznačena time što vodeni nosač je fiziološka otopina.
The formulation of claim 6 for use in treating a disease or disorder in a human subject, wherein the suitable medium or solvent is Ringer's solution. 
8. = Formulacija u skladu s patentnim zahtjevom 6, naznačena time što je namijenjena upotrebi u liječenju bolesti ili poremećaja kod ljudskog subjekta, gdje je pogodni medij ili otapalo Ringerova otopina.
Patent Document 5: International Publication Ser. 
Datum međunarodne objave:
A pharmaceutical composition for treating a tumor characterized by comprising at least one of the antibodies or functional fragments of the antibodies according to claims 1 to 18 and 30 to 32 and at least one therapeutic agent for cancer. 
Farmaceutska kompozicija za liječenje tumora naznačena time da sadrži najmanje jedno od antitijela ili funkcionalnih fragmenata antitijela prema patentnim zahtjevima 1 do 21 i najmanje jedan terapijski agens za rak.
centrifuging the resulting suspension at 3000 rpm for 5' at 4°C; 
centrifugiranje dobivene suspenzije na 3000 okretaja u minuti u trajanju od5 minuta na;
One embodiment of the invention is directed to the above method of recycling a solid support for cultivation of anchorage-dependent cells wherein the aqueous solution in step (b) is Water For Injection (WFI). 
Druga izvedba ovoga izuma se odnosi na spomenuti postupak za recikliranje krutih potpora za uzgoj stanica koje potrebuju pričvršćivanje, gdje vodena otopina u koraku (b) je voda za injektiranje (Water For Injecton - JVFI).
In this example, the duration of the active OFDM symbol may be 448 µs (at 4k FFT mode for 8MHz bandwidth CATV systems) or 597 µs (at 4k FFT mode for 6MHz bandwidth CATV systems). And, the duration of the active OFDM symbol for 6MHz bandwidth systems may be denoted as 448 x (8/6) µs or 597.33 µs more precisely. 
Postupak prema zahtjevu 9, gdje je vrijednost aktivnog OFDM polja trajanja simbola jedna od 448 us na 4k brzih Fourierovih transformacija (FFT), mod za prijenosni sustav od 8 MHz širine pojasa i 448 x (8/6) us na 4k FFT mod za prijenosni sustav od 6 MHz širine pojasa.
A capsule according to any one of claims 1-4, wherein the at least one projection is circumferential with respect to the capsule. 
Kapsula prema jednom od patentnih zahtjeva 1-2, pri čemu najmanje jedan ispupčeni dio (127) je raspoređen po obodu u odnosu na kapsulu (119).
The method of claim 7, wherein the tetraalkylammonium halide is tetrabutylammonium iodide. 
Postupak prema zahtjevu 10, naznačen time da tetraalkilamonijev halid je tetrabutilamonijev jodid.
Thus, the invention yields a DNA construct comprising a sequence of DNA that encodes a peptide of the invention. 
DNA konstrukt, naznačen time štosadrži slijed DNA u skladu s patentnim zahtjevom 9.
ii) the glycan is a naturally occurring mammalian glycoform; 
11) - glikan je prirodna glikoforma kod sisavca;
Pharmaceutical combination according to claim 1, in which the pharmaceutically acceptable salt of the compound N -[4-[2-(2-amino-4,7-dihydro-4-oxo-1 H -pyrrolo[2,3- d]pyrimidin-5-yl)ethyl]benzoyl]-L-Glutamic acid is its disodium salt form. 
Farmaceutska kombinacija za uporabu prema zahtjevu 1 ili 2, naznačena time, da farmaceutski prihvatljiva sol spoja N-[4-[2-(2-amino-4,7-dihidro-4-okso-1H-pirolo[2,3-d]pirimidin-5-il)etil]benzoil]-L-glutaminske kiseline, predstavlja njegov oblik dinatrijeve soli.
The present invention arises from these observations. 
Predmetni izum nastaje iz tih razmatranja.
An antibody binding to human CD38, wherein said antibody comprises human light chain and human heavy chain variable regions, wherein the light chain variable region comprises a VL CDR1 having the sequence as set forth in SEQ ID No:13, a VL CDR2 having the sequence as set forth in SEQ ID No:14 and a VL CDR3 having the sequence as set forth in SEQ ID No:15, and the heavy chain variable region comprises a VH CDR1 having the sequence as set forth in SEQ ID No:18, a VH CDR2 having the sequence as set forth in SEQ ID No:19 and a VH CDR3 having the sequence as set forth in SEQ ID No:20. 
Monoklonsko protutijelo koje se vezuje za humani CD38, pri čemu navedeno protutijelo sadrži humani laki lanac i varijabilne regije humanog teškog lanca, pri čemu varijabilna regija lakog lanca sadrži VL CDR1 koji ima slijed naveden u SEQ ID No: 13, VL CDR2 koji ima slijed naveden u SEQ ID br: 14 i VL CDR3 koji ima slijed naveden u SEQ ID br: 15, a varijabilno područje teškog lanca sadrži VH CDR1 koji ima slijed kao što je navedeno u SEQ ID br: 18, VH CDR2 koji ima slijed naveden u SEQ ID br:19 i VH CDR3 koji ima slijed kako je navedeno u SEQ ID br:20.
control the second release device based on the determined amount of second substance. The apparatus of paragraph 1, wherein the controller is further configured to: compare the determined amount of first substance to a predetermined limit; and control the first release device based on the comparison. 
E-cigareta (100) sukladno patentnom zahtjevu 1, naznačena time što je kontroler (124, 224) nadalje konfiguriran Za: usporedbu utvrđene količine prve tvari s unaprijed određenom granicom; i upravljati uređajem za prvo oslobađanje (118) na temelju usporedbe.
A pharmaceutical composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 28 and a pharmaceutically acceptable carrier or excipient. 
Sastav, naznačen time, da sadrži učinkovitu količinu spoja ili farmaceutski prihvatljive soli spoja prema patentnom zahtjevu 1 i farmaceutski prihvatljiv nosač ili ekscipijent.
at least an absorbing layer (120); 
- < najmanje jedan apsorbirajući sloj (120);
The use according to embodiment 15 or 16, wherein the foreseen occurrence of ischemia and reperfusion injury is organ transplantation. 
Upotreba u skladu s patentnim zahtjevom 14, naznačena time što do očekivane pojave ishemije i reperfuzijske ozljede dolazi nakon presađivanja organa.
Advantages of the present invention can be summarized as follows: 
Prednosti predloženog izuma mogu se zbirno prikazati kako slijedi:
Embodiments: A compound of Formula I: wherein 
Spoj naznačen time, da ima formulu I: u čemu
A VZV gE antigen for use according to claim 6, wherein the VZV gE antigen is delivered in a prime boost approach before the live attenuated VZV. 
VZV antigen gE namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što se VZV antigen gE unosi u pristupu s početnim stimulansom prije živog oslabljenog VZV.
The formulation according to claim 1 or 2, wherein the salt is sodium chloride or potassium chloride. 
Formulacija u skladu s patentnim zahtjevima 1 ili 2, pri čemu je sol natrijev klorid ili kalijev klorid.
Compounds of formula (XII) may in turn be prepared by reaction of compounds of formula (XIII) with compounds of formula (XIV): 
Spojeve formule (XII) može se pak dobiti reakcijom spojeva formule (XIII) sa spojevima formule (XIV): s
For preparing suppositories, a low melting wax, such as an admixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. 
Za pripremu ljekovitih čepića, voskovi niskog tališta, kao što je smjesa glicerida masnih kiselina ili kakao maslaca, se prvo rastali i zatim se aktivni sastojak homogeno dispergira u tome, na primjer miješanjem.
performed in perfusion mode. The method according to any one of claims 1 to 9, wherein the one or more cells is cultured in at least 100 L of the supplemented basal cell culture media. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što se jednu ili više stanica uzgaja u najmanje 100 l kompletiranog osnovnog medija za uzgoj stanica.
The compound according to claim 1, wherein the compound is of the formula: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što spoj ima formulu:
an optical isomer of the compound, wherein the optical isomer is the enantiomer of the compound; and 
optički izomer spoja, pri čemu optički izomer je enantiomer spoja; i
The composition according to claim 2 wherein the SFA is selected from the group consisting of 16:0 (palmitic acid) and 18:0 (stearic acid), and mixtures of the foregoing. 
Pripravak u skladu sa zahtjevom 2 naznačen time da je SFA odabrana 1z skupine koju čine 16:0 (palmitinska kiselina) i 18:0 (stearinska kiselina), te smjese prethodno navedenih kiselina.
receiving, by the target eNB, a special data packet with an end marker from the source eNB through the X2 interface, wherein the special data packet received from the source eNB does not contain user data; and 
Postupak prema bilo kojem zahtjevu od 1 do 3, naznačen time da, kada target eNB prosljeđuje pakete korisničkih podataka isporučene od SGW prema UE nakon prijema posebnog paketa podataka od izvorišnog eNB, ciljni eNB ne prosljeđuje poseban paket podataka prema UE.
The range of phosphorylation was calculated from the positive (vehicle plus ATP) and negative (vehicle minus ATP) control values. 
Raspon fosforilacije izračunat je iz pozitivnih (nosač + ATP) i negativnih (nosač - ATP) kontrolnih vrijednosti. b) Test proliferacije KB stanica pokrenut EGFR-om
drive motors that determine the movement of said litters (12). 
pogonske motore koji određuju pomicanje navedenih nosiljki (12), ležaj je naznačen time što dodatno sadrži:
The attenuated virus of item 1, wherein the virus is a DNA, RNA, double-stranded, or single-stranded virus. 
Oslabljeni virus prema zahtjevu 1., naznačen time što virus je DNK, RNK, dvolančani, ili jednolančani virus.
an optical conductor arranged in said housing, 
optički vodič smješten u kućištu, *
It should be further noted that the present invention is defined and limited only by the scope of the appended claims. A communication method comprising: receiving resource assignment information including a plurality of bits that indicate activation or deactivation statuses of respective downlink component carriers, the downlink component carriers being secondary downlink component carriers added to a primary component carrier which is always activated, each downlink component carrier corresponding to one bit included in the plurality of bits, and the one bit indicating that a corresponding downlink component carrier is to be activated or deactivated, wherein when any one bit among the plurality of bits indicates that its corresponding secondary component carrier should be activated, the plurality of bits further indicate a sounding reference signal, SRS, transmission request; 
Komunikacijska metoda sadržeći: prijem informacija o raspoređivanju resursa, uključujući pluralitet bitova koji pokazuju statuse aktivacije ili deaktivacije odgovarajućih nosača komponenti silazne veze, nosači komponenti silazne veze su sekundarni nosači komponenti silazne veze dodani primarnom nosaču komponenti koji je uvijek aktiviran, svaki nosač komponenti silazne veze odgovara jednom bitu koji je uključen u pluralitet bitova, i taj jedan bit pokazuje da li se treba aktivirati ili deaktivirati odgovarajući nosač komponenti silazne veze, naznačeno time da kad bilo koji bit među pluralitetom bitova ukazuje da treba aktivirati odgovarajući sekundarni nosač komponenti, pluralitet bitova dalje označava zahtjev za prijenos sondirajućeg referentnog signala, SRS; aktivaciju ili deaktivaciju svakog od nosača komponenti silazne veze sukladno informacijama o raspoređivanju resursa; i prijenos SRS prijenosa na aktiviranim sekundarnim nosačima komponenti.
The blender container 106 also includes a base 110, selectively removable lid 104, 105, and a base member 110 that is coupled to an agitating means 108 . 
Posuda mješalice 106 također uključuje postolje 110, uklonjiv poklopac 104, 105,1 bazu 110 koja je spojena na dio za miješanje 108.
The method of claim 16, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:66 residues 1-378. 
Polipeptid iz patentnog zahtjeva 1, koji sadrži aminokiselinsku sekvencu u skladu sa SEK ID BR:35 ostaci 1-378.
The solid was washed with pentane (3×30 mL) and dried under vacuum at RT to give a white powder (m=8.51 g). 
Krutina se ispere s pentanom (3 x 30 mL) i osuši pod vakuumom pri sobnoj temperaturi da se dobije bijeli prah (m = 8,51 g).
Turbidity was measured at 488nm and converted to an absolute specific turbidity (t) as described above, based on IL-2 concentration in the samples. 
Zamućenost se mjerila pri 488nm i konvertirala u apsolutnu specifičnu zamućenost (T) kako je gore opisano, bazirano na koncentraciji IL-2 u uzorcima.
Preferably, the caloric value of the sugar replacement composition should not exceed 200 kcal/100 g, more specifically 150 kcal/100 g. 
Kalorijska vrijednost sastavine koja zamjenjuje šećer ne bi trebala biti veća od 200 kcal/100 g, čemu se daje prednost, a još se veća prednost da je kalorijskoj vrijednosti od 150 kcal/100 g.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-iljamid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
A combination according to claim 8, wherein the active compound (c) is selected from the group consisting of (a) PDE IV inhibitors and (b) B2 agonists. 
Kombinacija u skladu s patentnim zahtjevom 8, naznačena time, da je djelatna tvar (c) odabrana iz skupine koja se sastoji od (a) inhibitora PDE IV 1 (b) f2 agonista.
the hardening of the impregnated strips of material. 
Datum podnošenja europske prijave patenta:
Since the compounds of the invention are susceptible to degradation in acid to neutral media, the above-mentioned granules or tablets are preferably coated with an enteric coating which protects the active compound from acid degradation as long as the dosage form remains in the stomach. 
Budući da su spojevi izuma osjetljivi na degradaciju u kiselom do neutralnom mediju, gore spomenute granule ih tablete su prvenstveno obložene s vanjskim omotačem koji štiti aktivni spoj od degradacije s kiselinom sve dok oblik doze ostaje u želucu.
Use of a compound as claimed in any of claims 1-4 in the manufacture of a medicament for the treatment of a condition in a mammal for which modulation of dopamine D3 receptors is beneficial. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1-20, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje psihoze ili psihotičnog stanja, ili zloupotrebe tvari.
An indolizine derivative as claimed in claim 9, wherein R1a represents a hydroxy group, or a pharmaceutically acceptable salt thereof. 
Derivat indolizina prema zahtjevu 8, gdje R'* predstavlja hidroksi skupinu, ili prolijek, ili farmaceutski prihvatljiva sol.
Product was extracted with EtOAc and washed with sodium bicarbonate solution and with water. 
Produkt je bio ekstrahiran s EtOAc 1 ispran s otopinom natrij bikarbonata 1 s vodom.
The compound of claim 17, or a pharmaceutically acceptable salt thereof, wherein Aris selected from the group consisting of phenyl, substituted phenyl, thiophen-yl, substituted thiophen-yl, pyridinyl, substituted pyridinyl, thiazolyl, substituted thiazolyl, bicyclic aryl, substituted bicyclic aryl, bicyclic heteroaryl, and substituted bicyclic heteroaryl. 
Spoj prema zahtjevu 17, ili njegova farmaceutski prihvatljiva sol, naznačen,a time, da Ar je odabran iz skupine koju čine: fenil, supstituirani fenil, tiofen-il, supstituirani tiofen-il, piridinil, supstituirani piridinil, tiazolil, supstituirani tiazolil, biciklički aril, supstituirani biciklički aril, biciklički heteroaril i supstituirani biciklički heteroaril.
Intermediate 36 was prepared (79% yield) following the procedure for intermediate 35 using intermediate 34. 
Intermedijer 36 je pripremljen (79% prinos) praćenjem postupka za Intermedijer 35 primjenom Intermedijera 34.
The antibody or functional protein according to Claim 9, which has an IC50 less than 1µM, preferably less than 500nM, preferably less than 200nM as measured in BMP6 Smad1 phosphorylation assay in MC3T3-E1 cell line in the presence of sclerostin. 
Protutijelo ili njegov dio koji veže antigen prema zahtjevu 9, naznačeno time da ima vrijednost ICsy manju od 1 uM, poželjno manju od 500 nM, poželjno manju od 200 nM kako je mjereno sa BMP6 Smad1 testom fosforilacije kod MC3T3-E1 stanične linije u prisutnosti sklerostina.
The formulation of claim 1, wherein the pH dependently soluble polymeric material of the outer layer is a blend of at least two different polymers having a pH threshold of about pH 6 and above. 
Formulacija lijeka s odloženim otpuštanjem sukladno u jednom od prethodnih patentnih zahtjeva, naznačeno time, da je drugi polimerni materijal spoj najmanje dva različita polimera koji imaju prag na pH od pH 6 ili više.
A method for controlling a rotary pressure device, wherein the rotary pressure device comprises: a motor for providing torque to rotary pressure means; 
Rotacijski uređaj za tlak kojim se može električno upravljati sukladno zahtjevu 1, pri čemu je rotacijsko tlačno sredstvo bušilica, svrdlo, alat za bušenje ili vijak.
The aqueous formulation of item 15, wherein the pH is 4. 
Vodena formulacija u skladu s patentnim zahtjevom 9, naznačena time što je pH 4.
(iii)mixing the hydrophilic solvent with the hydrophobic solvent under suitable conditions to form the composition comprising a polyaphron dispersion; 
miješanje hidrofilnog otapala s hidrofobnim otapalom u prikladnim uvjetima kako bi se dobio pripravak koji sadrži poliafronsku disperziju;
Finally, also the driving of the displacements of the capsule holder 21 are mechanically coupled to said main action. 
Na kraju, također 1 pogoni za premještanja držača čahure 21 su mehanički povezani s navedenim glavnim djelovanjem.
The adherent cells for use or the article of manufacture for use of claim 1 or claim 2, wherein said adherent cells express or secrete 
Stanice ili proizvodni artikl, namijenjeni upotrebi u skladu s patentnim zahtjevima 1 ili 2, naznačeni time što navedene adherentne stanice imaju fenotip stromalnih matičnih stanica.
the additional therapeutic agent is selected from the group consisting of anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, anti-pancreatic agents, lipid lowering agents, appetite suppressants, treatments for heart failure, treatments for peripheral arterial disease and anti-inflammatory agents. 
dodatna djelatna tvar se izabire iz grupe koja obuhvaća anti-dijabetike, anti-hiperglikemike, tvari protiv hiperinzulinemije, anti-retinopatike, anti-neuropatike, anti-nefropatike, anti-aterosklerotike, anti-ishemike, antihipertenzive, tvari protiv pretilosti, anti-dislipidemike, anti-dislipidemike, antihiperlipemike, tvari protiv hipertrigliceridemije, tvari protiv hiperkolesterolemije, tvari protiv restenoze, tvari protiv pankreatitisa, sredstva za snižavanje lipida, supresore apetita, lijekove za zatajenje srca, lijekove za periferne arterijske bolesti i protu-upalna sredstva.
a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having 50% or less of the protease activity of a wild-type non-mutated Tsp or is a knockout mutated Tsp gene; 
mutirani Tsp gen, pri čemu mutirani Tsp gen kodira Tsp protein koji ima 50% ili manje aktivnosti proteaze od divljeg tipa ne-mutiranog Tsp ili je „knockout“ mutirani Tsp gen;
for each one of said first number of batches of said materials to be mixed: 
zasvaki od navedenog prvog broja šarža navedenih materijala koje treba pomiješati: -
According to a further aspect, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament to treat an immunologic disorder, as defined hereinabove. 
Upotreba spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 14, ili njegove farmaceutski prihvatljive soli, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje imunološkog poremećaja,
The folding aspect blocks the main entrance thereby not allowing the bees to exit the beehive. 
Na taj način ona zatvara glavni ulaz i ne dozvoljava pčelama izlazak.
The process of claim 9 wherein the activated cysteinamide is H-Cys(Npys)-NH2. 
Postupak prema patentnom zahtjevu 9, naznačen time, da aktivirani cisteinamidni ostatak jest H-Cys(Npys)-NH..
A process for forming the compound of Formula I in claim 1, comprising a step of reacting a compound of formula V 
Postupak za dobivanje spoja formule I, definiranog u Zahtjevu 1, koji se sastoji od koraka reagiranja spoja formule
Step (a) is preferably carried out on a chelating sepharose column, such as a chelating sepharose fast flow column, having Zn2+ ions chelated. 
Korak (a) se poželjno provodi na koloni s helirajućom sefarozom poput kolone s helirajućom sefarozom za brzi protok koja sadrži helirane ione Zn"*.
The compounds of the present invention can be used in combination with CDK4 and/or 6 inhibitors. 
Lijek za uporabu prema zahtjevu 14 ili 15, pri čemu se lijek koristi u kombinaciji s radioterapijom.
with an amide under conditions suitable for forming an amide solvate of the compound of formula II; and contacting the amide solvate with an aqueous base comprising sodium ions under conditions suitable for forming the compound of formula I. In a particular embodiment, the compound of formula I is a hydrate, such as a hexahydrate. 
Oo=R-0H OH TI s amidom pod uvjetima pogodnim za nastajanje amidnog solvata spoja s formulom II; te b) kontaktiranje amidnog solvata s vodenom bazom koja sadrži natrijeve ione pod uvjetima pogodnim za nastajanje spoja s formulom I.
optionally recycling to step a) the stream of products derived from the oxychlorination reactor, from which the 1,2-dichloroethane has been extracted, optionally containing an additional stream of ethane previously introduced in one of steps b) to f), after having been optionally purged of gases and/or after an optional additional treatment in order to eliminate the chlorinated products contained therein; and subjecting the 1,2-dichloroethane so obtained to a pyrolysis thus producing vinyl chloride. 
HR P20110849 T1 struja produkata dobivenih iz reaktora za oksidaciju za kloriranje, iz koje je ekstrahiran 1,2-dikloroetan, proizvoljno sadrži dodatnu struju etana koja je prethodno uvedena u jednom od koraka b) do £f), se proizvoljno Teciklira u korak a) nakon što je proizvoljno očišćena od plinova i/ili nakon proizvoljne dodatne obrade kako bi se uklonili u njemu sadržani klorirani produkti; 1 dobiveni 1,2-dikloroetan je podvrgnut pirolizi te se tako dobiva vinil klorid.
Milling machine according to claim 1, characterized in that a drive rotation as well as a milling rotation and a forward feed motion are producible by means of hydraulic oil pump motors. 
Glodalica (100, 100a-100e) prema jednom od prethodnih zahtjeva, naznačena time, da su pogonska rotacija (AR, AR1), kao i rotacija glodanja (FR, FR1) i pomicanje prema naprijed (VB1-VB4) generirani pomoću hidrauličkih motora s pumpicom za ulje.
A composition comprising a humanized anti-beta7 antibody according to any one of claims 1 to 15 and a pharmaceutically acceptable carrier and optionally a second biopharmaceutical agent or chemotherapeutic agent. 
Sastav, naznačen time, da obuhvaća humanizirano anti-beta7 protutijelo prema bilo kojem zahtjevu 1 do 21 i farmaceutski prihvatljiv nosač.